GLP-1 RAs: Psychiatric, Cognitive, and Quality of Life Effects
This meta-analysis examines the impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RAs), medications used for obesity and diabetes, on the mental health and quality of life of patients. The study analyzed data from 80 randomized clinical trials involving over 107,000 participants with overweight, obesity, or diabetes. Crucially, it found no significant increase in the risk of serious or […]
Novo Nordisk Partners with Telehealth for Wegovy Promotion
May 23, 2025Stat + by Katie Palmer https://ro.co/ https://lifemd.com/ Stat + reports on the evolving landscape of GLP-1 drug marketing, noting a shift in the relationship between major pharmaceutical companies like Novo Nordisk and telehealth providers. After previously battling telehealth companies offering compounded versions of their drugs, Novo Nordisk is now collaborating with specific telehealth platforms, including Ro and LifeMD. This partnership […]
Cysteine Deficiency Drives Weight Loss by Depleting CoA
This research paper explores the impact of amino acid restriction on weight loss, focusing on the unique effects of cysteine deficiency. The study demonstrates that cysteine restriction in mice, particularly those with compromised cysteine synthesis, leads to rapid and significant weight loss, primarily through fat reduction. This weight loss is linked to the activation of stress responses, reduced levels of key metabolites like CoA, and resulting metabolic inefficiency, […]
MCED Test Performance in Obese Individuals
This abstract evaluates a multi-cancer early detection (MCED) blood test specifically designed for individuals with obesity, a group at higher risk for several cancers often without standard screening. The study investigated the test’s ability to accurately detect cancer and identify the tissue of origin using a two-step methylation profiling method. Results showed the test had a high positive predictive value (PPV) and reasonable sensitivity, […]
Fractyl Rejuva GLP-1 Gene Therapy Data at ASGCT 2025
The sources discuss Fractyl Health’s Rejuva GLP-1 gene therapy platform, highlighting preclinical data presented at ASGCT 2025 for its candidate RJVA-001. This research indicates that a single dose of RJVA-001 in animal models durably improves metabolic markers related to type 2 diabetes and obesity, achieving similar effects as existing GLP-1 drugs but with significantly lower systemic exposure, potentially leading to fewer […]
GLP-1 Use and Fatigue
ChatGPTMay 26, 2025 Fatigue or low energy is a commonly reported side effect among users of GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound), but it is not as well characterized or studied as gastrointestinal effects. Here’s what is currently known: 🔍 What We Know About Fatigue and GLP-1 Use ✅ PrevalenceFatigue is reported […]
GLP-1 Microdosing Trends and Risks
WSJ article discusses the growing trend of microdosing GLP-1 medications, like Ozempic and Zepbound, which are primarily used for weight loss and diabetes management. Some individuals are taking smaller or less frequent doses than prescribed, often motivated by cost savings, a desire to reduce side effects, or the belief in potential health benefits beyond weight loss. While some doctors […]
Metabolic Changes and Therapies in Aging Humans
This scientific article examines the connection between aging and metabolic changes in humans. It focuses on age-related alterations in adipose tissue, muscle, and liver, noting how sedentary habits worsen these effects, while physical activity can help mitigate them. The text also explores potential therapeutic interventions, including caloric restriction, exercise, and novel drug approaches, aimed at maintaining healthy metabolism later in life. The […]
GLP-1 RA vs Bariatric Surgery and Cancer Risk
Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort studyWolff Sagy, Yael et al. eClinicalMedicine, Volume 83, 103213 This paper presents an observational, retrospective cohort study comparing the incidence of obesity-related cancer (ORC) in adults with obesity and diabetes treated with first-generation GLP-1 receptor agonists (GLP-1 RAs) versus bariatric metabolic surgery (BMS). […]
Rewiring Brain Energy Regulation in Alzheimer’s Disease
This scientific overview examines recent research suggesting that GLP-1 receptor agonists, a class of medications already used for diabetes and obesity, show promise in treating Alzheimer’s disease. The article highlights a study indicating these agonists can reduce amyloid plaques and improve symptoms in mice by activating the AMPK signaling pathway. This activation appears to influence neuronal amyloid-beta metabolism and boost microglial cells’ ability to […]